Adhera Therapeutics, Inc.

PharmaceuticalsNorth Carolina, United States11-50 Employees

Adhera Therapeutics, Inc. is a Durham, North Carolina-based pharmaceutical company focused on developing and commercializing late-stage, non-addictive pain therapeutics that rely on combinations of already approved drugs to address arthritis, pain, hypertension, and oncology. Its programs include next-generation formulations designed to mitigate edema side effects associated with established drugs, enabling higher dosing and potential alternatives to opioids, and the firm is also exploring anticancer applications for FAP and colorectal cancer.

The firm promotes its FDA-approved Prestalia hypertension therapy through a patient-centric care program that reports adherence rates exceeding 80%. This program targets resistant hypertension, a patient segment estimated to comprise about 22% of hypertensive individuals, with compliance and counseling shown to improve outcomes in this group. Its pipeline includes Perindopril as monotherapy, Prestalia as a combination therapy (Perindopril/Amlodipine), the Atorvastatin/Perindopril pairing for hypertension and lipid disorders, and IT-102 and IT-103 for hypertension and pain. In 2022, Zahed Subhan was appointed chief executive officer, marking a leadership change as the company advances its programs.

Sign up for free to view info

Email Format Employee directory